CAM2029 is a novel depot formulation of octreotide, a somatostatin analogue, administered subcutaneously once monthly.

Munters Group AB posted the largest decline among large stocks during the session, plunging 11.0%, followed by Camurus AB shares, which declined 9.8%. Shares of Lifco AB Series B fell 5.8%.

The FDA issued a complete response letter (CRL) to Camurus, dealing a setback to the Swedish drugmaker’s efforts to bring its ...

The regulator cited deficiencies at a third-party manufacturing facility. Camurus is seeking approval for its ...

In a summary of current health news: the CDC investigates bird flu in Washington, David Joyner becomes CVS CEO, China tackles ...

The FDA handed a CRL to the Swedish biotech Camurus for its hormone disorder therapy over “facility-related deficiencies” at ...

The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due ...

Schally, PhD-- who won a Nobel Prize for discovering the hormones used by the brain to control growth, reproduction, and ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Jefferies analyst Brian Balchin maintained a Buy rating on Camurus AB (CAMRF – Research Report) today and set a price target of ...

The FDA is looking at four events for the remainder of October, one of which is an advisory committee meeting for a dual SGLT ...

Jefferies analyst Brian Balchin maintained a Buy rating on Camurus AB (CAMRF – Research Report) on October 11 and set a price target of ...